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Abstract  
 
Objective: Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is a 
collagen receptor that belongs to the inhibitory immunoreceptor tyrosine-based 
inhibition motif (ITIM)-containing receptor family.  It is an inhibitor of signalling via the 
immunoreceptor tyrosine-based activation motif (ITAM)-containing collagen receptor 
complex, GPVI-FcRγ-chain.  It is expressed on hematopoietic cells, including 
immature megakaryocytes, but is not detectable on platelets.  Although the inhibitory 
function of LAIR-1 has been described in leukocytes, its physiological role in 
megakaryocytes and in particular in platelet formation has not been explored.  In this 
study, we investigate the role of LAIR-1 in megakaryocyte development and platelet 
production by generating LAIR-1-deficient mice.   
Approach and Results: Mice lacking LAIR-1 exhibit a significant increase in platelet 
counts, a prolonged platelet half-life in vivo and increased proplatelet formation in 
vitro.  Interestingly, platelets from LAIR-1-deficient mice exhibit an enhanced 
reactivity to collagen and the GPVI-specific agonist collagen-related peptide (CRP) 
despite not expressing LAIR-1, and mice showed enhanced thrombus formation in 
the carotid artery following ferric chloride injury.  Targeted deletion of LAIR-1 in mice 
results in an increase in signalling downstream of the GPVI-FcRγ-chain and integrin 
αIIbβ3 in megakaryocytes due to enhanced Src family kinase (SFK) activity. 
Conclusions: Findings from this study demonstrate that ablation of LAIR-1 in 
megakaryocytes leads to increased SFK activity and downstream signalling in 
response to collagen that is transmitted to platelets, rendering them hyper-reactive 
specifically to agonists that signal through Syk tyrosine kinases, but not to G protein-
coupled receptors. 
 
 
Key words:  LAIR-1, ITIM, SFK, megakaryopoiesis, thrombocytosis, platelet 
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Running title: hyperactive platelets in LAIR-1 KO mice 
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Erk1/2: extracellular signal-regulated kinase 
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3 
 
Introduction 
For an adequate function of platelets and megakaryocytes, a tight balance between 
stimulatory and inhibitory signals is required.  Inhibitory receptors that carry 
immunoreceptor tyrosine-based inhibition motifs (ITIMs) in their cytoplasmic tail play 
an essential role in the regulation of megakaryocyte and platelet reactivity1,2.  
Platelets express at least five ITIM-containing receptors, PECAM-1, CEACAM-1, 
CEACAM-2, TLT-1 and G6b-B.  Platelet endothelial cell adhesion molecule-1 
(PECAM-1) is a well characterised ITIM-containing receptor that has been reported 
to inhibit signaling via the immunocreceptor tyrosine-based activation motif (ITAM)-
containing collagen receptor complex GPVI-FcR γ-chain and thrombin-mediated 
platelet activation1.  Carcinoembryonic antigen-related cell adhesion 
molecule (CEACAM)-1 was shown to have a similar function in platelets to that of 
PECAM-13.  CEACAM-2 is a novel platelet immunoreceptor that has been shown to 
act as a negative regulator of platelet GPVI-FcR γ-chain and of the hemi-
immunoreceptor tyrosine-based activation motif (hemi-ITAM)-containing podoplanin 
receptor CLEC-2 pathways4.  In contrast, the platelet-specific ITIM-containing 
triggering receptor expressed in myeloid cells-like transcript-1 (TLT-1) is up-
regulated on the surface of activated platelets and plays a role in supporting, rather 
than inhibiting, platelet activation5.  Unique among ITIM-containing receptors, G6b-B 
is highly abundant in mature megakaryocytes and platelets and is constitutively 
phosphorylated and associated with the SH2 domain-containing non-transmembrane 
protein-tyrosine phosphatases (PTPs) Shp1 and Shp26.  We recently reported that 
G6b-B is a major regulator of megakaryocyte/platelet homeostasis and platelet 
reactivity2,7. 
Leukocyte-associated immunoglobulin (Ig)-like receptor-1 (LAIR-1), also known 
as CD305, is a collagen receptor that belongs to the inhibitory Ig-ITIM family8.  LAIR-
1 is widely expressed on hematopoietic cells, including immature megakaryocytes, 
but is not detectable in platelets9.  LAIR-1 possesses a single extracellular Ig 
variable domain and 2 ITIMs in its cytoplasmic tail that mediate its inhibitory capacity 
through the interaction with Shp1, Shp2 and C-terminal Src kinase (Csk)10,11.  LAIR-
1 binds with higher affinity than GPVI to glycine-proline-hydroxyproline (GPO) repeat 
motifs in collagen12,13.   
Previously, we have shown that co-expression of LAIR-1 with GPVI in 
transiently transfected DT40 chicken B cells mediates strong inhibition of collagen-
mediated activation of a NFAT reporter assay14.  Several studies have shown that 
LAIR-1 also functions as an inhibitory receptor on immune cells and is involved in 
the regulation of hematopoietic cell differentiation15-18.  In addition, recent studies 
report that LAIR-1 is essential for acute myeloid leukaemia development19,20.  
However, the role of LAIR-1 in megakaryocyte development and platelet formation is 
not known. 
In this study, we investigate the role of LAIR-1 in megakaryopoiesis and platelet 
activation.  We show that mice lacking LAIR-1 exhibit a mild thrombocytosis, 
increased proplatelet formation in vitro and produce hyperactive platelets.  
Furthermore, LAIR-1-deficient megakaryocytes exhibit increased reactivity to 
collagen and increased αIIbβ3 outside-in signalling despite having normal cell 
surface levels of the collagen receptors GPVI and the integrin α2β1, and of the 
fibrinogen integrin αIIbβ3.  The increase in reactivity observed in LAIR-1-deficient 
megakaryocytes is also seen in platelets, suggesting transfer of activation signals 
from megakaryocytes to platelets.  
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Materials and Methods 
Materials and Methods are available in the online-only Data Supplement. 
 
Results  
LAIR-1 and GPVI are inversely expressed during megakaryopoiesis in vitro 
We first analysed the expression of LAIR-1 alongside other major surface 
glycoproteins during mouse megakaryocyte differentiation by flow cytometry.  Bone 
marrow progenitor cells were isolated from wild-type (WT) mice and cultured in the 
presence of 20 ng/ml Tpo for 8 days.  Cells were harvested every day and receptor 
surface expression measured by flow cytometry.  LAIR-1 was highly expressed on 
mouse hematopoietic stem cells and its expression decreased during 
megakaryopoiesis (Figure 1A-B), whereas the opposing relationship was observed 
for the collagen receptors, GPVI and α2β1.  Importantly, GPVI and α2β1 were highly 
expressed on mouse platelets, but LAIR-1 expression was not detectable by flow 
cytometry or western blot (Figure 1B and Figure 2Ai).  These results demonstrate 
that GPVI and LAIR-1 are inversely expressed during mouse megakaryopoiesis in 
vitro as is the case for human megakaryocytes9.  However, a subset of intermediate 
megakaryocytes expressed both activatory and inhibitory receptors for collagen.  In 
this population of megakaryocytes, the GPVI-specific agonist convulxin, which does 
not bind to LAIR-114, stimulated phosphorylation of LAIR-1 (Figure 1C).  
 
LAIR-1-deficient mice exhibit mild thrombocytosis and increased platelet half-
life 
To study the physiological function of LAIR-1, we generated LAIR-1-deficient mice 
(Supplemental Figure I).  Homozygous LAIR-1 knockout mice (LAIR-1 KO) were 
born at Mendelian frequencies, were fertile, and survived for >25 weeks with no overt 
growth or developmental defects.  By western blotting, LAIR-1 was not detectable in 
immature megakaryocytes from LAIR-1 KO mice, nor in platelets from WT and LAIR-
1 KO mice (Figure 2Ai).  Haematological analysis revealed that LAIR-1 KO mice 
displayed a mild thrombocytosis (25% increase in platelet count) with unchanged 
platelet volume (Figure 2Aii-iii).  Platelets and megakaryocytes from LAIR-1 KO 
mice have normal organelles and granule content as assessed by transmission 
electron microscopy (Figure 2B and not shown).  LAIR-1 KO mice did not exhibit a 
bleeding diathesis following tail injury (Supplemental Figure II).  In addition, 
megakaryocyte counts were normal in the spleen and bone marrow of LAIR-1 KO 
mice (Supplemental Figure IIIA,C) and reticulin staining revealed no evidence of 
tissue damage in the spleen and bone marrow of LAIR-1 KO mice (Supplemental 
Figure IIIB).  To investigate whether the thrombocytosis was the result of decreased 
platelet clearance, platelet half-life was measured in vivo.  Interestingly, we found 
that the half-life of platelets from LAIR-1 KO mice was increased by 17% (Figure 
2C), thereby accounting for the mild thrombocytosis. 
 
Normal megakaryocyte development, but increased proplatelet formation in 
LAIR-1 KO mice 
We next investigated whether LAIR-1 regulates megakaryocyte differentiation in vitro 
by analysing their DNA content during development.  The absence of LAIR-1 had no 
effect on megakaryocyte development as shown by a normal ploidy pattern (Figure 
3Ai-ii) and cellular appearance (data not shown).  LAIR-1-deficient megakaryocytes 
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exhibited a marked increase in spreading on a fibrinogen-coated surface (Figure 
3Bi-ii), despite having normal levels of αIIbβ3 (Table 1), suggesting increased 
outside-in integrin signalling.  In addition, the percentage of LAIR-1-deficient 
megakaryocytes forming proplatelets was elevated and an increased branching of 
proplatelets was also observed (Figure 3Ci-iii).  These results demonstrate that 
LAIR-1 exhibits a tonic inhibitory effect on megakaryocyte spreading on fibrinogen 
and on platelet formation.  Since LAIR-1 is a collagen receptor, we have also 
investigated megakaryocyte spreading and proplatelet formation on collagen.  We 
show that LAIR-1-deficient megakaryocytes spread normally on collagen, and that 
neither WT nor LAIR-1 KO megakaryocytes formed proplatelets on collagen 
(Supplemental Figure IV and data not shown).   
 
Unchanged thrombopoietin signalling, but increased reactivity to collagen in 
LAIR-1-deficient megakaryocytes 
Having demonstrated increased spreading and proplatelet formation in LAIR-1 KO 
megakaryocytes, we investigated the molecular basis of these defects.  We focused 
on Tpo- and integrin-mediated Erk1/2 phosphorylation and SFK activation, as we 
have previously demonstrated that Erk1/2 plays a critical role in primary 
megakaryocyte differentiation, motility, and proplatelet formation21, and that SFKs 
regulate megakaryocyte differentiation and platelet production21.  Phospho-specific 
antibodies were used to monitor Erk1/2 and SFK activation.  Tpo-mediated Erk1/2 
activation was normal in LAIR-1-deficient megakaryocytes (Figure 4Ai), consistent 
with the normal growth and ploidy of these cells (Figure 3Ai-ii).  SFK activation, 
which lies upstream of Erk1/2, was, however enhanced in resting LAIR-1-deficient 
megakaryocytes compared to controls (Figure 4Aii), suggesting that basal SFK 
activity was increased.  Despite the extent of basal SFK activation being increased, 
SFKs were phosphorylated to the same extent on their activation loop (Tyr-418) by 
Tpo in control and mutant megakaryocytes (Figure 4Aii).  In addition, basal and 
integrin αIIbβ3-mediated Erk1/2 and SFK activation were increased in fibrinogen-
adhered LAIR-1-deficient megakaryocytes (Figure 4Bi-ii), consistent with the 
increased megakaryocyte spreading and proplatelet formation (Figure 3Bi-ii and 
Figure 3Ci-iii). 
Since LAIR-1 is an inhibitory collagen receptor, we investigated GPVI 
signalling in LAIR-1-deficient megakaryocytes.  Interestingly, we show that 
phosphorylation of SFK Tyr-418, the tyrosine kinase Syk on its activation loops (Syk 
Tyr-519/520) and of its downstream target PLCγ2 on Tyr-1217, all of which are 
indicators of activation,  were significantly increased in LAIR-1-deficient resting and 
convulxin-stimulated megakaryocytes (Figure 4Ci-iii), despite having a normal 
surface level of GPVI (Table 1).  However, phosphorylation of Src, Fyn and Lyn at 
their C-terminal inhibitory tyrosine residues, Tyr-529, Tyr-530 and Tyr-507 
respectively were unchanged (Supplemental Figure V). 
 
LAIR-1-deficient mice exhibit increased platelet function 
Platelet aggregation and ATP secretion were measured to investigate whether the 
absence of LAIR-1 in megakaryocytes alters platelet function.  An increase in 
response to collagen, which binds to GPVI and α2β1, and to the GPVI-specific 
agonist CRP, but not to convulxin, was observed in platelets from LAIR-1 KO mice 
using light transmission aggregometry (Figure 5Ai-iii, Figure 5Bi-iii and 
Supplemental Figure VIAi-ii respectively), despite having normal expression 
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levels of the collagen receptors GPVI and α2β1 (Table 2).  The expression levels of 
integrin αIIbβ3, GPIbα and of the ITIM-containing receptors G6b-B and PECAM-1 
remained unchanged (Table 2).  Platelet aggregation in response to thrombin, 
U46619 and ADP were normal in LAIR-1 KO mice compared with WT controls 
(Figure 5Ci-iii and Supplemental Figure VIBi-iii).  Similar results were observed 
using a 96-well plate aggregation assay (Supplemental Figure VIC), which 
confirmed greater sensitivity of platelets from LAIR-1 KO mice to collagen-induced 
aggregation.  Consistent with this observation, P-selectin exposure, fibrinogen 
binding and integrin activation were also increased in response to CRP, but not to 
thrombin in LAIR-1 KO mice (Figure 5D and Supplemental Figure VID).   
We next investigated platelet spreading on a fibrinogen-coated surface as this 
is an important aspect of platelet function that is dependent on the integrin αIIbβ3 for 
adhesion and cytoskeletal remodelling22.  Platelets from LAIR-1 KO mice exhibited 
an increase in spreading on fibrinogen in comparison to WT platelets (Figure 6Ai-ii), 
suggesting that LAIR-1 negatively regulates this process.  However, when pre-
activated with 0.1 U/mL thrombin, platelets from LAIR-1 KO mice spread normally 
(Figure 6Ai-ii).  Therefore, LAIR-1 is involved in the regulation of αIIbβ3 outside-in 
signalling, but not the regulation of protease-activated receptor-4 (PAR-4) signalling.   
Whole cell lysates prepared from fibrinogen-spread and non-adherent platelets 
exhibited an increase in phosphorylation of Src Tyr-418 and Syk Tyr-519/520, in 
platelets from LAIR-1 KO mice (Figure 6Bi-ii), consistent with the increase in 
spreading, whereas phosphorylation of Src Tyr-529, Fyn Tyr-530 and Lyn Tyr-507 
were unchanged (Supplemental Figure VII), providing  further evidence of a 
proximal signalling defect.  Integrin αIIbβ3 outside-in signalling also regulates clot 
retraction. To study whether the loss of LAIR-1 alters clot retraction, clot formation 
was induced in PRP by addition of a high concentration of thrombin (10 U/mL) in the 
presence of 2 mM Ca2+ and was monitored over time.  No differences were observed 
and the excess fluid extruded after clot retraction was similar in WT and LAIR-1 KO 
mice (Supplemental Figure VIII). 
 
Increased GPVI-mediated signalling in platelets from LAIR-deficient mice 
The molecular basis of the increase in reactivity to collagen and CRP was 
investigated by monitoring protein phosphorylation.  Western blotting revealed a 
general increase in tyrosine phosphorylation in response to CRP in platelets from 
LAIR-1KO mice (Figure 7Ai), including FcR γ-chain and SFK Tyr-418 (Figure 7Aii).  
Further investigation revealed increased phosphorylation Syk Tyr-519/520 and 
increased phosphorylation of its downstream target PLCγ2 Tyr-1217 (Figure 7Bi-ii), 
whereas phosphorylation of Src Tyr-529, Fyn Tyr-530 and Lyn Tyr-507 were 
unchanged (Supplemental Figure IXAi-ii).  This demonstrated that deletion of 
LAIR-1 in megakaryocytes results in increased SFK activity and downstream GPVI 
signalling.  Platelets from LAIR-1 KO mice spread normally on collagen in vitro as 
shown by normal surface area coverage (Supplemental Figure IXBi-ii).  However, 
interestingly they formed larger aggregates on a collagen matrix under arterial shear, 
and covered a larger surface area (Figure 7C).  The physiological role of LAIR-1 in 
arterial thrombosis was also investigated in vivo using two distinct assays, namely 
the laser- and ferric chloride-induced injury models.  We found that, in the laser injury 
model in cremaster arterioles, thrombus formation was unaffected in LAIR-1 KO 
mice (Figure 7Di-ii and Supplemental Videos SI and SII).  However, using the 
ferric chloride injury model in the carotid artery, we show that the rate and extent of 
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thrombus formation is significantly increased in the LAIR-1 KO mice compared with 
litter-matched WT mice (Figure 7Ei-iii and Supplemental Videos SIII and SIV). 
These findings correlate with the increase in platelet reactivity to collagen 
demonstrated in vitro. 
Taken together, these findings demonstrate that the lack of inhibition of ITAM 
signalling in LAIR-1-deficient megakaryocytes is transferred to platelets, resulting in 
enhanced GPVI-mediated signalling through increased SFK activity resulting in 
greater platelet activation and a predisposition to thrombosis that is dependent on 
the type of injury and vasculature. 
 
Discussion 
In this study, we investigated the role of LAIR-1 in megakaryocyte development and 
platelet production by generating and characterising LAIR-1 KO mice.  We 
demonstrate for the first time that LAIR-1 is a negative regulator of platelet 
production and reactivity to collagen and fibrinogen.  Mice lacking LAIR-1 exhibit a 
25% increase in platelet counts, a prolonged platelet half-life in vivo and increased 
proplatelet formation in vitro.  Interestingly, platelets from LAIR-1 KO mice exhibit an 
enhancement of reactivity to GPVI and αIIbβ3 agonists, despite not expressing 
LAIR-1 and having normal receptor levels, and formed larger aggregates on a 
collagen matrix under arterial shear.  As a consequence, LAIR-1 KO mice exhibited 
increased thrombus formation following ferric chloride-induced carotid artery injury, 
which has been shown to be GPVI-dependent23, but not following laser-induced 
injury of cremaster arterioles, which is tissue factor and thrombin-dependent23.  In 
addition, the composition of the vessel wall and rheological characteristics differ 
between these models, which likely influences the differences observed.  Findings 
from this study demonstrate that ablation of LAIR-1 in megakaryocytes leads to an 
increased SFK activity and downstream signalling in response to collagen that is 
transmitted to platelets, rendering them hyper-reactive specifically to agonists that 
signal through SFKs, but not through G protein-coupled receptors. 
We first examined the expression of collagen receptors (LAIR-1, GPVI, α2β1) 
and surface-marker expression of CD34, GPIbα and αIIbβ3 at different stages of 
megakaryocyte maturation.  During murine megakaryocyte maturation, the inhibitory 
collagen receptor LAIR-1 is downregulated while the activating collagen receptor 
GPVI is upregulated.  However, a subset of cells co-express these collagen 
receptors with opposite functions, as previously shown during human 
megakaryopoiesis9.  These findings raise the question of why LAIR-1 would be 
expressed at these early stages of megakaryocyte differentiation.  One possible 
explanation is that this could prevent the excessive activation of immature 
megakaryocytes exposed to surrounding collagens.  The main collagen receptors 
expressed by megakaryocytes are the high affinity integrin α2β1, the low affinity 
ITAM-containing receptor GPVI-FcRγ-chain complex, and LAIR-1, which has the 
same binding site as GPVI, but with a considerably higher affinity12. 
Deletion of LAIR-1 in mice leads to an increase in the number of circulating 
platelets compared to litter-matched controls.  Despite this, megakaryocyte counts 
were normal in the spleen and bone marrow of LAIR-1 KO mice and reticulin staining 
revealed no evidence of tissue damage in the spleen and bone marrow of LAIR-1 
KO mice.  We show that platelet half-life is increased thereby accounting for the mild 
thrombocythemia.  Recent studies have highlighted the role of glycan modification on 
platelet surface proteins mediating platelet clearance24,25.  Indeed, lifespan of 
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circulating platelets is determined by sialic acid loss that triggers platelet removal by 
the hepatic Ashwell-Morell receptor (AMR)25.  Circulating platelets become 
desialylated as they age, however, in preliminary studies, we did not observe a 
change in staining for sialic acid in platelets from LAIR-1 KO mice.  Platelet survival 
also depends on the interplay between pro-survival and pro-apopotic signals26 and a 
change in either of these could underlie the increase in platelet life-span.   
We also found that LAIR-1 KO mice exhibit normal megakaryocyte 
development as measured by ploidy levels but enhanced proplatelet formation on 
fibrinogen suggesting that platelet biogenesis is enhanced, providing a further basis 
for the increase in platelet count.  We investigated the molecular mechanism 
underlying the increased proplatelet formation exhibited by the LAIR-1-deficient 
megakaryocytes by examining phosphorylation of key signalling proteins 
downstream of integrin αIIbβ3.  We found that Erk1/2 and SFK activation were 
increased in fibrinogen adherent LAIR-1-deficient megakaryocytes as is similarly the 
case in platelets, which also exhibit increased GPVI signalling. This raises the 
possibility that a change in SFK activity in megakaryocytes could potentially underlie 
both the increase in platelet production and reactivity to GPVI and integrin αIIbβ3 
agonists observed in platelets.  Despite the increase in SFK activity, megakaryocytes 
and platelets from LAIR-1 KO mice spread normally on collagen.  We suspect this is 
due to the moderate phenotype and synergistic effects of multiple receptors and 
feedback pathways involved, masking any defect. 
Previous work by Meyaard et al demonstrated that LAIR-1 mediates its 
inhibitory effect through its interaction with Shp1 and Shp210.  LAIR-1 has also been 
shown to recruit Csk to the plasma membrane10, which inhibits SFK activity by 
phosphorylating the C-terminal inhibitory tyrosine residue.  Here, we report that 
LAIR-1 KO megakaryocytes exhibit increased basal SFK activity that is then 
transferred to platelets, rendering them hyper-responsive to collagen and fibrinogen, 
and represents a new paradigm of how platelet reactivity can be modulated.  
Although the mechanism underlying the increase in SFK activity in LAIR-1 KO 
megakaryocytes remains undefined, we hypothesize it is due to decreased 
compartmentalization of Shp1, Shp2 or Csk at the plasma membrane, all of which  
have been implicated in regulating SFK activity either directly by modulating the 
relative level of phosphorylation of the C-terminal inhibitory and activation loop 
tyrosine residues, or indirectly through regulation of adaptor proteins that unclamp 
and activate SFKs27.  It should be noted that phosphorylation of the C-terminal 
inhibitory tyrosine residue of SFKs does not always correlate with SFK activity, 
whereas phosphorylation of the activation loop does28.  Further work is needed to 
elucidate the exact mechanism underlying the increase in SFK activity in LAIR-1 KO 
megakaryocytes, and why it remains elevated in resting platelets.  
The present study adds to the growing evidence that ITIM-containing 
receptors are critical regulators of platelet formation and function and sheds new 
light on the role of the collagen receptor LAIR-1 in regulating the basal activating 
state of megakaryocytes.  LAIR-1 is therefore the third ITIM receptor that has been 
shown to regulate platelet formation.  Mice deficient in PECAM-1 exhibit a significant 
decrease in platelet recovery following immune thrombocytopenia and increased 
platelet reactivity to collagen29.  In contrast, mice lacking G6b-B have a pronounced 
thrombocytopenia and increased GPVI shedding2   
This study establishes that deletion of LAIR-1 in megakaryocytes disrupts the 
homeostatic balance of megakaryocytes and platelets, shifting the balance to a 
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prothrombotic state due to concomitant increases in platelet count and reactivity.  
Moreover, this study demonstrates that changes in the activation state of signalling 
proteins within the megakaryocytes leads to changes in platelets that are released 
into the circulation.  Alteration in the megakaryocyte signalling proteins can therefore 
influence platelet functional responses.  While substantial progress has been made 
in understanding the mechanisms that regulate thrombopoiesis and platelet 
formation, we have yet to fully uncover what signalling pathways initiate and regulate 
these processes.  A better understanding of these processes may result in therapies 
that stimulate immediate platelet production from existing megakaryocytes.   
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Highlights 
 
• In this study, we show that deficiency of the ITIM-containing receptor LAIR-1 
in megakaryocytes results in thrombocytosis and production of hyperactive 
platelets.  
 
• We demonstrate that ablation of LAIR-1 in megakaryocytes leads to an 
increased Src family kinase activity and downstream signalling in response to 
collagen that is transmitted to platelets, rendering them hyper-reactive.   
 
• As a consequence, we show that LAIR-1 KO mice exhibited increased 
thrombus formation following ferric chloride-induced carotid artery injury. 
 
• Our findings reveal a novel function of the ITIM-containing receptor LAIR-1 in 
thrombopoiesis and provide further insight into the molecular mechanisms 
regulating megakaryocyte and platelet hyperactivity that could lead to a 
prothrombotic state.  
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Tables 
Table 1: Megakaryocyte surface glycoprotein expression in LAIR-1 KO mice 
Data represents mean values of the mean fluorescence intensity ± SEM, ***P < 
0.001 
 
 
 
 
Table 2: Platelet surface glycoprotein expression in LAIR-1 KO mice 
Data represents mean values of the mean fluorescence intensity ± SEM 
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Figure legends 
 
Figure 1: LAIR-1 and GPVI are inversely expressed during megakaryopoiesis 
in vitro.  (A) Expression of CD34, the collagen receptors LAIR-1, GPVI and α2β1, 
and GPIbα and αIIbβ3 were measured at indicated days of in vitro murine 
megakaryopoiesis by flow cytometry.  % of positive cells are represented, mean ± 
SEM n = 4-8.  (B) Expressions of the collagen receptors LAIR-1, GPVI and α2β1, 
and of the integrin αIIbβ3 were measured on day 0, 1, 5, 8 of in vitro murine 
megakaryopoiesis and in mouse platelets.  Ploidy was evaluated in parallel.  
Representative histograms from three independent experiments are shown.  Grey 
histograms represent isotype control staining and open histograms represent the 
different receptor staining.  (C) LAIR-1 is phosphorylated in primary mouse bone 
marrow-derived megakaryocytes.  Bone marrow-derived megakaryocytes were 
treated with 100 µM pervanadate (Perv), 30 µg/mL convulxin (Cvx) or with PBS 
alone for 15 minutes at 37°C and lysed with NP40 lysis buffer.  Cell lysates were 
subjected to immunoprecipitation with anti-mouse LAIR-1 antibody coupled to protein 
G beads.  Proteins were separated by SDS-PAGE and western blotted using anti-
phosphotyrosine (upper panel) and anti-LAIR-1 (lower panel) antibodies.  
Representative blots from n = 3 independent experiments. 
 
Figure 2: LAIR-1 KO mice exhibit a mild thrombocytosis.  (Ai) Whole cell lysates 
of bone marrow-derived megakaryocytes and washed platelets from litter-matched 
wild-type (WT) and LAIR-1 knockout (KO) mice were western blotted with anti-
mouse LAIR-1 antibody and tubulin as loading control.  Representative western blots 
from n = 4 mice/genotype is represented.  (Aii) Platelet counts and (Aiii) volumes 
from litter-matched WT (n = 38) and LAIR-1 KO mice (n = 36) were measured.  
Mean ± SEM; ***P < 0.001.  (B) Normal ultrastructure and organelle content of 
platelets from LAIR-1 KO mice.  Transmission electron micrographs of ultrathin 
sections platelets from litter-matched WT and LAIR-1 KO mice are shown.  AG, α-
granules; DG, dense granules; OCS, open canalicular system; M, mitochondria.  (C) 
Platelet half-life was measured by flow cytometry after quantification of the number 
of biotin+αIIbβ3+ platelets in the circulation of litter-matched WT and LAIR-1 KO mice 
daily pre-/post-injection of biotin-N-hydroxysuccinamide.  Mean ± SEM n = 4-8 
mice/genotype/time point; **P < 0.01; ***P < 0.001.   
 
Figure 3: LAIR-KO mice exhibit normal megakaryocyte development but 
increased proplatelet formation.  (A) Ploidy of bone marrow-derived 
megakaryocytes from litter-matched WT and LAIR-1 KO mice were quantified after 
propidium iodide staining by flow cytometry.  (Ai) Representative profiles are shown; 
n = 4-6 mice/genotype.  (Aii) The percentage of 2-128N ploidy cells was quantified.  
Mean ± SEM; n = 4-6 mice/genotype.  (B)  Bone marrow-derived megakaryocytes 
from litter-matched WT and LAIR-1 KO mice were plated on fibrinogen-coated 
surfaces for 3 hours.  Images of spread megakaryocytes stained with Alexa-Fluor 
568 phalloidin were taken.  (Bi) Representative images (n = 4-6 mice/genotype) and 
(Bii) surface area mean ± SEM are shown.  (C) Bone marrow-derived 
megakaryocytes from litter-matched WT and LAIR-1 KO mice were plated on 
fibrinogen-coated surfaces for 5 hours.  (Ci) Representative images of proplatelet 
forming megakaryocytes stained with FITC-αIIbβ3 were taken.  (Cii) Percent of 
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megakaryocytes forming proplatelets (n = 4-6 mice/genotype, mean ± SEM) and 
proplatelet mean areas are represented (**P < 0.01, scale bar: 20 µm).   
 
Figure 4: Thrombopoietin and integrin, collagen signalling in LAIR-1-deficient 
megakaryocytes.  (A) Bone marrow-derived megakaryocytes from litter-matched 
WT and LAIR-1 KO mice were stimulated with 50 ng/mL thrombopoietin (Tpo) for 10 
minutes at 37°C.  Whole cell lysates were western blotted with (i) anti-phospho-
Erk1/2 (p-Erk1/2), anti-pan Erk1/2 (Erk1/2), and (ii) anti-Src p-Tyr418 and anti-pan 
Src antibodies.  Representative blots and densitometry quantification from n = 3-5 
independent experiments/genotype (mean ± SEM; *P < 0.05).  (B)  Bone marrow-
derived megakaryocytes from litter-matched WT and LAIR-1 KO mice were plated on 
100 µg/ml fibrinogen-coated surfaces for 3 hours at 37°C.  Whole cell lysates were 
prepared of non-adherent (NA) and fibrinogen (fib) adherent megakaryocytes and 
were western blotted with (Bi) anti-phospho-Erk1/2 (p-Erk1/2), anti-pan Erk1/2 
(Erk1/2), and (Bii) anti-Src p-Tyr418 and anti-pan Src antibodies.  Representative 
blots and densitometry quantification from n = 3-5 independent 
experiments/genotype (mean ± SEM; *P < 0.05).  (C) Bone marrow-derived 
megakaryocytes from litter-matched WT and LAIR-1 KO mice were stimulated with 
30 µg/ml convulxin for 15 minutes at 37°C.  Whole cell lysates were western blotted 
with anti-Src p-Tyr418, anti-Syk p-Tyr519/520 and anti-PLCγ2 p-Tyr1217 antibodies.  
Membranes were stripped and reblotted with anti-pan Src, anti-pan Syk and anti-pan 
PLCγ2 antibodies.  (Ci) Representative blots and (Cii) densitometry quantification 
from n = 4 independent experiments/genotype (mean ± SEM; *P < 0.05, **P < 0.01).   
 
Figure 5: Increased platelet reactivity in LAIR-1 KO mice.  Platelet aggregation 
and ATP secretion of washed platelets were measured by lumi-aggregometery in 
response to (Ai-iii) 1, 3 and 10 µg/mL collagen, (Bi-iii) 1, 3 and 10 µg/mL collagen-
related peptide (CRP), (Ci) 0.06, 0.09 and 0.3 U/mL thrombin, (Cii) 0.25, 0.5 and 1 
µM U46619 and (Ciii) 1, 3 and 10 µM ADP.  Representative traces are shown, n = 4-
8 mice/genotype/condition.  Quantification of time to 25% platelet aggregation and 
ATP secretion in response to collagen (Ai-iii) and to CRP (Bi-iii) were measured.  
Mean ± SEM are represented (*P < 0.05, **P < 0.01).  (D) P-selectin expression and 
fibrinogen binding of platelets from LAIR-1 KO mice in response to 1, 3 and 10 
µg/mL CRP and 0.06 U/mL thrombin were measured.  Geometric mean fluorescence 
intensity (MFI) ± SEM is represented; n = 3-5 mice/genotype; **P < 0.01.   
 
Figure 6: Increased platelet spreading in LAIR-1 KO mice. (A) Basal and 
thrombin (0.1 U/mL)-activated platelets were plated on a fibrinogen-coated surface.  
(Ai) Representative differential interference contrast (DIC) and phalloidin-stained 
images of platelets.  (Aii) Surface area of individual platelets in DIC images was 
measured; n = 3-5 mice/genotype, 250-500 platelets/condition; mean ± SEM; **P < 
0.01; scale bar: 5 µm.  (B) Increased αIIbβ3 signalling in LAIR-1 KO mice.  
Platelets from litter-matched WT and LAIR-1 KO mice were plated on 100 µg/mL 
fibrinogen-coated surfaces for 45 minutes at 37°C.  Whole cell lysates were prepared 
of non-adherent (NA) and fibrinogen (fib) adherent platelets.  (Bi)  Equal amounts of 
total protein were resolved by SDS-PAGE and Western blotted with an anti-Src p-
Tyr418, anti-Syk p-Tyr519/520 and anti-PLCγ2 p-Tyr1217.  Membranes were 
subsequently stripped and reblotted with anti-Src, anti-Syk and anti-PLCγ2 
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antibodies.  Blots are representative of 4 independent experiments.  (Bii) Band 
intensities were quantified from 4 separate experiments (mean ± SEM; *P < 0.05).   
 
Figure 7: Increased GPVI-mediated signalling in platelets from LAIR-1 KO 
mice.  (A) Whole cell lysates of resting and 1 µg/mL collagen-related peptide (CRP)-
stimulated platelets from litter-matched WT and LAIR-1 KO mice were western 
blotted with anti-phosphotyrosine (p-Tyr) and anti-Src pTyr418 and membranes were 
stripped and reblotted with actin antibody.  (Ai) Representative blots and (Aii) 
densitometry quantification from n = 3 independent experiments/genotype (mean ± 
SEM; *P < 0.05, **P < 0.01).  (B) Whole cell lysates of resting and 1 µg/mL CRP-
stimulated platelets from litter-matched WT and LAIR-1 KO mice were western 
blotted with anti-Syk p-Tyr519/520, and anti-PLCγ2 p-Tyr1217 antibodies.  
Membranes were stripped and reblotted with anti-pan Syk and anti-pan PLCγ2 
antibodies.  (Bi) Representative blots and (Bii) densitometry quantification from n = 4 
independent experiments/genotype (mean ± SEM; *P < 0.05).  (C) Anticoagulated 
blood was flowed through collagen-coated capillary tubes.  DIC images of fixed 
platelets on collagen fibrils after being flowed through collagen-coated capillary tubes 
at 1,000 s−1 for 4 minutes.  (Ci)  Images are representative of 3 independent 
experiments.  Scale bar: 10 µm.  (Cii) Area covered by platelet thrombi was 
measured.  Data presented are means (± SEM) of 3 independent experiments (**P < 
0.01).  (D)  Laser injury-induced thrombus formation in vivo.  Mice were injected 
with Dylight488-conjugated anti-GPIbβ antibody (0.1 µg/g body weight, X488).  
Arterioles in cremaster muscles of recipients were subsequently injured by laser, and 
the accumulation of platelets (green) into the thrombi was assessed.  (Di) 
Representative composite brightfield and fluorescence images from X488-labeled 
platelets after laser injury of arteriole are shown.  Scale bar: 10 µm.  (Dii) Each curve 
represents the median integrated thrombus fluorescence intensity in arbitrary units 
(a.u.) for 23-73 thrombi induced in 4-12 mice/genotype.  See also supplementary 
videos SI and SII.  (E) Ferric chloride-induced thrombus formation in vivo.  Mice 
were injected with DyLight488-conjugated anti-GPIbβ antibody (0.1 µg/g body 
weight, X488).  Exposed carotid arteries were injured with 10% ferric chloride for 3 
minutes and the accumulation of platelets (green) into the thrombi was assessed.  
(Ei) Representative fluorescence images from X488-labeled platelets after ferric 
chloride injury of carotid are shown.  Scale bar: 200 µm.  (Eii) Each curve represents 
the median integrated fluorescence density in arbitrary units (a.u.) for 10 
mice/genotype.  (Eiii) Area under the curve of the integrated fluorescence density is 
represented (mean ± SEM; *P < 0.05 using a Mann-Whitney test).  See also 
supplementary videos SIII and SIV. 
 
 
 
 
Materials and Methods  
 
Mice 
LAIR-1 knockout (KO) mice were generated by Taconic Artemis as shown in 
Supplemental Figure 1 and bred as heterozygotes.  Wild-type (WT) littermates were 
used as controls.  All procedures were undertaken with United Kingdom Home Office 
approval in accordance with the Animals (Scientific Procedures) Act of 1986. 
 
Chemicals 
Horm collagen was from Takeda (Munich, Germany).  Convulxin was from Enzo Life 
Sciences (Exeter, UK).  Human fibrinogen was from Enzyme Research Laboratories 
(Swansea, UK). FITC-conjugated rat-α-mouse GPVI, α2, αIIbβ3, GPIbα, P-selectin, 
phycoerythrin (PE)-conjugated JON/A, DyLight488-labeled anti-GPIbβ and rat IgG 
antibodies were from Emfret Analytics (Würzburg, Germany).  Anti-mouse CD31-
FITC was from BD Biosciences (San Jose, USA).  Anti-mouse LAIR-1 purified and 
PE-conjugated antibodies and Armenian Hamster IgG Isotype controls were from 
eBioscience (Wembley, UK).  FITC-conjugated anti-mouse CLEC2 and rat IgG 
antibodies were from Serotec (Kidlington, UK).  The α-phospho-tyrosine (4G10) and 
PTP1B antibodies was from Millipore (Abingdon, UK).  The α-Src-pY418, α-Src-
pY529, pan Src were from Life Technologies (Paisley, UK).  The α SykpY525/526, 
α-PLCγ2-pY1217, α-Lyn-pY507 antibodies were from Cell Signalling Technology 
(Hitchin, UK).  The α Fyn-p-Y530 antibody was from Abcam (Cambridge, UK).  The 
pan Lyn, pan Fyn, Csk, Shp1, Shp2 were from Santa Cruz Biotechnology 
(Heidelberg, UK).  Horseradish peroxidase-conjugated secondary antibodies and 
ECL were purchased from Amersham Biosciences (GE Healthcare, Bucks, UK).  All 
other reagents were purchased from Sigma-Aldrich (Poole, UK) or from sourced as 
previously described1. 
 
Platelet flow cytometry 
Platelet surface glycoprotein expression was measured in whole blood using specific 
FITC-conjugated antibodies and analyzed with a FACSCalibur flow cytometer and 
CellQuest software (Becton Dickinson).  Resting and activated platelets were fixed 
and stained with anti-P-selectin FITC-conjugated antibody or fibrinogen Alexa-Fluor 
488 conjugated2.  
 
Platelet aggregation and secretion 
Blood was collected from the inferior vena cava of CO2-asphyxiated mice into 1/10 
(v/v) acid-citrate-dextrose anticoagulant, and washed platelets (2 x 108/mL) were 
prepared3.  Platelet aggregation and adenosine triphosphate (ATP) secretion were 
simultaneously measured using a lumi-aggregometer (Chrono-Log, Havertown, PA).  
 
Platelet spreading 
Washed platelets (2 x 107/mL) from LAIR-1 KO and litter-matched WT mice were 
either preincubated with or without 0.1 U/mL thrombin for 5 minutes and placed on 
100 µg/mL fibrinogen-coated cover-slips, or placed on 100 µg/mL collagen-coated 
coverslips, for 45 minutes at 37°C4.  Platelets were fixed with 4% formalin 
permeabilized with 0.1% Triton X-100 and stained with Alex Fluor 568-phalloidin.  
Images were captured by differential interference contrast (DIC) or confocal 
reflection microscopy and surface areas of platelets were measured using ImageJ 
software. 
Platelet adhesion under flow 
Blood was collected into 5 U/mL heparin and 40 µM PPACK (D-phenylalanyl-L-
prolyl-L-arginine chloromethyl ketone), incubated for 10 minutes at 37°C with DiOC6  
(3,3′-dihexyloxacarbocyanine iodide) and perfused through collagen-coated (100 
µg/mL) glass microslide capillaries (1 × 0.1 mm) at 1,000 s-1 for 4 minutes at 37°C3.  
Capillaries were washed with modified Tyrode’s for 5 min at 1000 s-1 and DIC 
images were captured. 
 
Platelet biochemistry 
Washed platelets (4 x 108/mL) were stimulated with 1 µg/ml collagen-related peptide 
(CRP) at 37°C with stirring at 1200 rpm in an aggregometer.  Reactions were 
stopped with 2X SDS sample buffer to generate whole cell lysates (WCLs).  For 
integrin signaling, coverslips were coated with fibrinogen (100 µg/mL) overnight at 
4°C, blocked with denatured BSA (5 mg/mL) for 1 hour at room temperature, and 
washed with PBS before use.  Platelets were plated on fibrinogen for 45 minutes at 
37°C.  Non-adherent platelets were removed and lysed by addition of 2X lysis buffer 
(basal).  Adherent platelets were washed twice with Tyrode’s buffer then lysed with 
1X lysis buffer, incubated on ice for 10 minutes before scraping.  Equal amount of 
proteins were resolved on 4-12% NuPAGE Bis-Tris gradient gels and immunoblotted 
with primary antibodies and horseradish peroxidase-conjugated secondary antibody.  
Proteins were detected by enhanced chemiluminescence and autoradiography2. 
 
Preparation and culture of mouse megakaryocytes 
Bone marrow-derived megakaryocytes from LAIR-1 KO and litter-matched WT mice 
were cultured as previously described1,5,6.  Different stages of megakaryocyte 
maturation were identified by their ploidy profile and expression level of 
glycoproteins.  Throughout the study, we have used the subset of megakaryocytes 
which expresses both GPVI and LAIR-1. 
 
Megakaryocyte ploidy and surface receptor expression 
Surface receptor expression of αIIbβ3, GPIbα, GPVI and integrin α2β1, CLEC-2, 
G6b-B, PECAM-1 and LAIR-1 were measured on cultured bone marrow-derived 
megakaryocytes by flow cytometry with FITC-conjugated primary antibodies during 
megakaryocyte differentiation.  The DNA ploidy of megakaryocytes isolated by BSA 
gradient was analysed after anti-αIIbβ3 staining and DNA staining with propidium 
iodide (10 µg/mL).  Cells positive for αIIbβ3 were gated to analyse DNA content as 
described5. 
 
Megakaryocyte spreading and proplatelet formation in vitro 
Coverslips were coated with fibrinogen (100 µg/mL) or collagen (100 µg/mL) 
overnight at 4°C, blocked with denatured BSA (5 mg/mL) for 1 hour at room 
temperature, and washed with PBS before use.  Megakaryocytes were plated on a 
fibrinogen or collagen-coated surface for 3 (spreading) or 5 (proplatelet formation) 
hours at 37°C.  Adherent megakaryocytes were fixed with 4% formalin and 
permeabilized with 0.1% Triton X-100.  Actin fibres were stained with Alex Fluor 568-
phalloidin and megakaryocytes forming proplatelets with anti–mouse αIIbβ3-FITC 
antibody as described5.   
 
 
Megakaryocyte biochemistry 
Megakaryocytes were starved for 4 hours at 37°C in serum-free media following ex 
vivo differentiation and BSA gradient.  Whole-cell lysates were prepared from 
megakaryocytes stimulated for 10 minutes with 50 ng/mL thrombopoietin (Tpo) or 
from non-adherent and fibrinogen adherent megakaryocytes for 3 hours.  Equal 
amount of proteins were resolved on 4-12% NuPAGE Bis-Tris gradient gels and 
immunoblotted with primary antibodies and horseradish peroxidase-conjugated 
secondary antibody.  Proteins were detected by enhanced chemiluminescence and 
autoradiography2. 
 
Immunohistochemistry  
Femora and spleens from LAIR-1 KO and litter-matched WT mice were fixed in 
buffered formalin and embedded in paraffin.  Sections (5 µm) were stained with 
haematoxylin and eosin (H&E) and reticulin and examined with a Zeiss Axiovert 200 
inverted microscope using a 40X objective. 
 
Tail bleeding assay 
Blood loss was measured in anaesthetized 8-10 week old LAIR-1 KO mice and litter-
matched WT following excision of a 3 mm portion of the tail tip, as previously 
described2.  Mice were allowed to bleed until they lost either 15% blood volume 
(assuming a blood volume of 70 mL/kg) or for 30 minutes.  Normalized blood loss 
was determined by lost blood/body weight. 
 
Platelet half-life 
Whole blood was collected at various times post-intravenous injection of 150 µL of 4 
mg/mL N-hydroxysuccinimide ester (NHS)-biotin and percentage of biotin-labeled 
platelets was determined by flow cytometry, as described7. 
 
Clot retraction 
For clot retraction studies, 400 µL PRP, adjusted to a concentration of 
3×108 platelets/µL, were supplemented with 2 mM CaCl2 and fibrinogen 2 mg/mL. 
Clotting was induced by addition of high thrombin concentrations (10 U/mL)8. 
Subsequent clot retraction was monitored at 37°C under non-stirring conditions and 
percentage of extruded serum was monitored at different time points. 
 
Laser-induced thrombus formation model 
Experiments were conducted on 20- to 25g LAIR-1 KO and litter-matched WT mice, 
as previously described9.  Mice were anesthetized intraperitoneally with Avertin (240 
µg/g body weight, 2,2,2-Tribromoethanol, Sigma-Aldrich).  The cremaster muscle 
surrounding the testicle was exteriorized and spread flat over an optically clear 
coverslip on a pedestal and continuously superfused with a bicarbonate-buffered 
saline (pH 7.4; 37°C) gassed with 5% CO2/95% N2.  Mice were injected with 
DyLight488-conjugated anti-GPIbβ antibody (0.1 µg/g body weight, X488) via the 
carotid artery.  Laser-induced thrombi were generated at the luminal surface of 
selected arterioles, as previously described10.  Real-time intravital brightfield and 
fluorescent images of the developing thrombus were captured simultaneously by 
confocal microscopy and analysed using Slidebook6 software (Intelligent Imaging 
Innovations). 
 
 
Ferric chloride-induced thrombus formation model 
Experiments were conducted on 20- to 30g LAIR-1 KO and litter-matched WT mice, 
as previously described10.  Mice were anesthetized intraperitoneally with Avertin (240 
µg/g body weight, 2,2,2-Tribromoethanol, Sigma-Aldrich).  Platelets were labelled by 
intravenous administration of DyLight488-conjugated anti-GPIbβ antibody (0.1 µg/g 
body weight, X488).  Right carotid arteries were exposed and filter paper (2 x 1 mm) 
soaked with 10% ferric chloride in PBS was applied for 3 minutes on the arterial 
adventitia.  Injury sites were imaged by time-lapse microscopy for 15 minutes, and 
images were analysed using Slidebook6 software (Intelligent Imaging Innovations).  
Background fluorescence values measured upstream of the injury site were 
subtracted from the thrombus-specific fluorescence.  Data are expressed as 
integrated fluorescence density. 
 
Statistical analysis 
Statistical significance was analysed using the unpaired Student’s t-test .  P < 0.05 
was considered statistically significant. 
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Supplemental Figure I.  LAIR-1 targeting strategy. 
Exons 1 and 2 have been replaced with a F3-flanked positive selection cassette (Puromycin 
resistance) expressed under the control of an eukaryotic promoter and containing a 
polyadenylation signal.  Homologous recombinant clones will be isolated using positive 
(Puromycin resistance) and negative (Thymidine kinase - Tk) selection.  The targeting vector 
has been generated using BAC clones from the C57BL/6J RPCIB-731 BAC library and will be 
transfected into the TaconicArtemis C57BL/6N Tac ES cell line.  Replacing the proximal 
promoter and exons 1 and 2 with the positive selection cassette in the targeted allele 
(=constitutive KO allele) should result in the loss of function of the Lair1 gene by deleting the 
translation initiation codon and the sequence encoding the signal peptide.  In addition, the 
deletion of the proximal promoter and the 5’UTR should prevent transcription of the Lair1 
messenger RNA.  Flp-mediated removal of the positive selection cassette also results in a 
constitutive KO allele.  Heterozygous mice (-/+) were intercrossed to generate homozygous 
wild-type and mutant mice.  The mice are viable, fertile, normal in size and do not display any 
gross physical or behavioural abnormalities. 
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Supplemental Figure II 
Supplemental Figure II.  LAIR-1 KO mice do not exhibit a bleeding diathesis 
following tail injury.  Normal blood loss of LAIR-1 KO (n = 10) mice compared with 
litter-matched wild-type (WT) mice (n = 9) in the tail bleeding assay (3 mm cut).  
Symbols represent individual mice.  Horizontal line represents mean. 
A 
Supplemental Figure III.  Normal haematopoiesis in LAIR-1 KO mice.  (A) H&E- and (B) 
reticulin-stained spleen and femur sections from litter-matched WT and LAIR-1 KO mice.  
Representative images from n = 5 mice/genotype, 8-10 fields of view per tissue sample, 
through five marrow or spleen sections.  Bright field images were obtained using a Zeiss 
Axiovert 200 inverted high-end microscope (Welwyn Garden City, UK) with a 20× objective.  
Arrowheads indicate megakaryocytes  (scale bar = 50 µm).  (C) Quantification of the number of 
megakaryocytes per field. 
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Supplemental Figure IV 
Supplemental Figure IV.  Normal megakaryocyte spreading on collagen. (A) Bone 
marrow-derived megakaryocytes from litter-matched WT and LAIR-1 KO mice were plated on 
collagen-coated surface (100 µg/mL) for 5 hours at 37oC.  Representative images of spread 
megakaryocytes (Alexa Fluor 488-phalloidin stained); scale bar represents 20 µm.  (B) 
Megakaryocyte surface area was measured; n = 3/genotype, 20-50 
megakaryocytes/genotype; mean ± SEM. 
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Supplemental Figure V. GPVI proximal signalling in LAIR-1 deficient megakaryocytes. 
Bone marrow-derived megakaryocytes from litter-matched WT and LAIR-1 KO mice were 
stimulated with 30 µg/mL convulxin for 15 minutes at 37°C.  Whole cell lysates were 
western blotted with anti-Src p-Tyr529, anti-Fyn p-Tyr530 and anti-Lyn p-Tyr507 antibodies.  
Membranes were stripped and reblotted with anti-Src, anti-Fyn and anti- Lyn antibodies.  (i) 
Representative blots and (ii) densitometry quantification from n = 3 independent 
experiments/genotype (mean ± SEM).  
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Supplemental Figure VI 
C 
Supplemental Figure VI.  Platelet reactivity in LAIR-1 KO mice.  (A) Platelet aggregation 
and ATP secretion of washed platelets were measured by lumi-aggregometry in response to 
(Ai-ii) 30 and 100 ng/mL convulxin and (Bi-iii) 0.03, 0.04 and 0.06 U/mL thrombin.  
Representative traces are shown, n = 10-11 mice/genotype/condition.  Quantification of time to 
area under the curve (AUC) of platelet aggregation and ATP secretion were measured.  Mean ± 
SEM are represented.  (C) 96-well microlitre plates (Greiner Bio-One, Stonehouse, 
Gloucestershire, UK) were precoated with hydrogenated gelatine (0.75% w/v) in PBS to block 
the surface activation of platelets before the addition of the platelet agonists. PRP or PPP was 
added into the appropriate control (agonist-free) and agonist-containing wells.  The plate was 
sealed with film and then placed on a heater/shaker at 37ºC to mix at 1200 rpm for 5 minutes.  
Absorbance was then measured at 650 nm on a standard 96-well plate reader.  Platelet 
aggregation was expressed as the maximal percent change in light transmittance from PRP 
wells in response to agonists, using PPP as reference, n = 3-4 mice/genotype/condition.  (D) 
JON/A binding of platelets from litter-matched WT and LAIR-1 KO mice in response to 1, 3 and 
10 µg/mL CRP and 0.06 U/mL thrombin were measured.  Geometric mean fluorescence 
intensity (MFI) ± SEM is represented; n = 6 mice/genotype; **P < 0.01. 
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Supplemental Figure VII 
Supplemental Figure VII.  Platelet αIIbβ3-integrin signalling in LAIR-1 KO mice.  Washed 
platelets from litter-matched WT and LAIR-1 KO mice were plated on fibrinogen-coated surface 
for 45 minutes at 37oC.  Whole cell lysates were prepared from non-adherent (NA) and 
fibrinogen-adherent (fib) platelets and were western-blotted with anti-Src p-Tyr529, anti-Lyn p-
Tyr507 and  anti-Fyn p-Tyr530.  Membranes were stripped and reblotted with anti-pan Src, anti-
Lyn and anti-Fyn.  (i) Representative blots and (ii) densitometry quantification from n = 3 
independent experiments/genotype (mean ± SEM). 
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Supplemental Figure VIII.  Normal clot retraction in LAIR-1 KO mice.  Clot retraction 
of platelets in platelet rich plasma (PRP) from litter-matched WT (n = 10) and LAIR-1 KO mice 
(n = 8) upon activation with 10 U/mL thrombin in the presence of 2 mM CaCl2 and 2 mg/mL 
fibrinogen.  % of extruded serum  over time is represented.  Values are mean ± SEM. 
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Supplemental Figure IX.  GPVI proximal signalling in platelets from LAIR-1 KO mice.  (A) 
Whole cell lysates of resting and 1 µg/mL collagen-related peptide (CRP)-stimulated platelets 
from litter-matched WT and LAIR-1 KO mice were western blotted with anti-Src p-Tyr529, anti-
Fyn p-Tyr530 and anti-Lyn p-Tyr507 antibodies.  Membranes were stripped and reblotted with 
anti-Src, pan Fyn and pan Lyn antibodies.  (Ai) Representative blots and (Aii) densitometry 
quantification from n = 3 independent experiments/genotype (mean ± SEM).  (B) Platelets from 
litter-matched WT and LAIR-1 KO mice were plated on collagen-coated surface (100 µg/mL) for 
45 minutes at 37oC.  (Bi) Representative confocal reflection and phalloidin-stained images of 
platelets; scale bar: 10 µm.  (Bii) Surface area of individual platelets in confocal reflection 
images was measured; n = 5/genotype, 140-220 platelets/genotype; mean ± SEM. 
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Supplemental Video I (for Figure 7D).  Laser-induced thrombus formation in an 
arteriole of a WT mouse.  WT mice were injected with DyLight488-conjugated anti-
GPIbβ antibody (X488) via the carotid artery.  Fluorescently-labelled platelets (green) are 
shown accumulating at the site of a laser-induced injury in an arteriole of the cremaster 
muscle.  A timer is show in the top left corner and a 10 µm scale bar in the bottom left 
corner.  Representative video of twenty-three thrombi induced in 4 WT mice. 
 
Supplemental Video II (for Figure 7D).  Laser-induced thrombus formation in an 
arteriole of a LAIR-1 KO mouse.  LAIR-1 KO mice were injected with DyLight488-
conjugated anti-GPIbβ antibody (X488) via the carotid artery.  Fluorescently-labelled 
platelets (green) are shown accumulating at the site of a laser-induced injury in an 
arteriole of the cremaster muscle.  A timer is show in the top left corner and a 10 µm 
scale bar in the bottom left corner.  Representative video of seventy-three thrombi 
induced in 12 KO mice.  
  
Supplemental Video III (for Figure 7E).  Ferric chloride-induced thrombus 
formation in the carotid artery of a WT mouse.  WT mice were injected with 
DyLight488-conjugated anti-GPIbβ antibody (X488) via the jugular vein.  Exposed carotid 
arteries from WT mice were injured with 10% ferric chloride for 3 minutes.  Fluorescently-
labelled platelets (green) are shown accumulating at the site of an injury over 15 minutes.  
A timer is shown in the top left corner and a 200 µm scale bar in the bottom left corner.  
Representative video of thrombus formation from 10 WT mice. 
 
Supplemental Video IV (for Figure 7E).  Ferric chloride-induced thrombus 
formation in the carotid artery of a LAIR-1 KO mouse.  LAIR-1 KO mice were injected 
with DyLight488-conjugated anti-GPIbβ antibody (X488) via the jugular vein.  Exposed 
carotid arteries from LAIR-1 KO mice were injured with 10% ferric chloride for 3 minutes.  
Fluorescently-labelled platelets (green) are shown accumulating at the site of an injury 
over 15 minutes.  A timer is shown in the top left corner and a 200 µm scale bar in the 
bottom left corner.  Representative video of thrombus formation from 10 LAIR-1 KO mice. 
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